Tags

Type your tag names separated by a space and hit enter

Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study.
Cephalalgia 1994; 14(4):297-300C

Abstract

This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks.

Authors+Show Affiliations

Service de Neurologie, Hôpital Saint Antoine, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

7954760

Citation

Chabriat, H, et al. "Combined Oral Lysine Acetylsalicylate and Metoclopramide in the Acute Treatment of Migraine: a Multicentre Double-blind Placebo-controlled Study." Cephalalgia : an International Journal of Headache, vol. 14, no. 4, 1994, pp. 297-300.
Chabriat H, Joire JE, Danchot J, et al. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia. 1994;14(4):297-300.
Chabriat, H., Joire, J. E., Danchot, J., Grippon, P., & Bousser, M. G. (1994). Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia : an International Journal of Headache, 14(4), pp. 297-300.
Chabriat H, et al. Combined Oral Lysine Acetylsalicylate and Metoclopramide in the Acute Treatment of Migraine: a Multicentre Double-blind Placebo-controlled Study. Cephalalgia. 1994;14(4):297-300. PubMed PMID: 7954760.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. AU - Chabriat,H, AU - Joire,J E, AU - Danchot,J, AU - Grippon,P, AU - Bousser,M G, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 297 EP - 300 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 14 IS - 4 N2 - This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks. SN - 0333-1024 UR - https://www.unboundmedicine.com/medline/citation/7954760/full_citation L2 - http://journals.sagepub.com/doi/full/10.1046/j.1468-2982.1994.1404297.x?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -